» Articles » PMID: 25284487

Inflammatory Dysregulation of Blood Monocytes in Parkinson's Disease Patients

Abstract

Despite extensive effort on studying inflammatory processes in the CNS of Parkinson's disease (PD) patients, implications of peripheral monocytes are still poorly understood. Here, we set out to obtain a comprehensive picture of circulating myeloid cells in PD patients. We applied a human primary monocyte culture system and flow cytometry-based techniques to determine the state of monocytes from PD patients during disease. We found that the classical monocytes are enriched in the blood of PD patients along with an increase in the monocyte-recruiting chemoattractant protein CCL2. Moreover, we found that monocytes from PD patients display a pathological hyperactivity in response to LPS stimulation that correlates with disease severity. Inflammatory pre-conditioning was also reflected on the transcriptome in PD monocytes using next-generation sequencing. Further, we identified the CD95/CD95L as a key regulator for the PD-associated alteration of circulating monocytes. Pharmacological neutralization of CD95L reverses the dysregulation of monocytic subpopulations in favor of non-classical monocytes. Our results suggest that PD monocytes are in an inflammatory predisposition responding with hyperactivation to a "second hit". These results provide the first direct evidence that circulating human peripheral blood monocytes are altered in terms of their function and composition in PD patients. This study provides insights into monocyte biology in PD and establishes a basis for future studies on peripheral inflammation.

Citing Articles

Skull bone marrow and skull meninges channels: redefining the landscape of central nervous system immune surveillance.

Liu L, Zhang X, Chai Y, Zhang J, Deng Q, Chen X Cell Death Dis. 2025; 16(1):53.

PMID: 39875352 PMC: 11775313. DOI: 10.1038/s41419-025-07336-2.


Infiltrating peripheral monocyte TREM-1 mediates dopaminergic neuron injury in substantia nigra of Parkinson's disease model mice.

Song W, Zhou Z, Zhang L, Shu H, Xia J, Qin X Cell Death Dis. 2025; 16(1):18.

PMID: 39809747 PMC: 11733277. DOI: 10.1038/s41419-025-07333-5.


Inhibition of neuroinflammation by GIBH-130 (AD-16) reduces neurodegeneration, motor deficits, and proinflammatory cytokines in a hemiparkinsonian model.

Bianchetti M, Ferreira A, Britto L Front Neuroanat. 2024; 18:1511951.

PMID: 39736920 PMC: 11684390. DOI: 10.3389/fnana.2024.1511951.


Autophagic signatures in peripheral blood mononuclear cells from Parkinson's disease patients.

Lee M, Kim J, Park D, Heo H, Kim J, Yoon J Mol Cells. 2024; 48(2):100173.

PMID: 39730076 PMC: 11786884. DOI: 10.1016/j.mocell.2024.100173.


Immune mechanisms and shared immune targets in neurodegenerative diseases.

Weiner H Nat Rev Neurol. 2024; 21(2):67-85.

PMID: 39681722 DOI: 10.1038/s41582-024-01046-7.


References
1.
Ahmed I, Tamouza R, Delord M, Krishnamoorthy R, Tzourio C, Mulot C . Association between Parkinson's disease and the HLA-DRB1 locus. Mov Disord. 2012; 27(9):1104-10. DOI: 10.1002/mds.25035. View

2.
Tuettenberg J, Seiz M, Debatin K, Hollburg W, VON Staden M, Thiemann M . Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients. Int Immunopharmacol. 2012; 13(1):93-100. DOI: 10.1016/j.intimp.2012.03.004. View

3.
Geissmann F, Jung S, Littman D . Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity. 2003; 19(1):71-82. DOI: 10.1016/s1074-7613(03)00174-2. View

4.
Ajami B, Bennett J, Krieger C, McNagny K, Rossi F . Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nat Neurosci. 2011; 14(9):1142-9. DOI: 10.1038/nn.2887. View

5.
Beier C, Schulz J . CD95/Fas in the brain--not just a killer. Cell Stem Cell. 2009; 5(2):128-30. DOI: 10.1016/j.stem.2009.07.008. View